Skip to main content

SL Science Holding Ltd

corporate_fare Company Profile

SL Science Holding Ltd

SLBT·NASDAQ·Life Sciences·CIK 0002070534

SL Science Holding Ltd is a biomedical company specialized in developing innovative cellular and gene therapies, conducting its business activities through its subsidiary, SL Bio. The holding company has no substantive business operations of its own. SL Science aims to utilize immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, with the goal of offering expansive medical applications for its products. Its proprietary technologies include Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. For its proprietary Armed-T Therapy, SL Science is engaged in active product design, in-vitro functional testing, and manufacturing process optimization. Armed-T is intended to enhance anti-cancer cytotoxicity by conjugating bispecific antibodies or other effector molecules to immune cells. As of the date of the report, the company has not initiated any formal good laboratory practice (GLP)-compliant in-vivo toxicity studies for Armed-T, and therefore no animal data are yet available. For its Gamma Delta T (GDT) Cell Culture Technology, SL Science has developed a proprietary ex-vivo expansion and activation process for T cells derived from peripheral blood mononuclear cells (PBMCs). Development work to date has included optimization of cytokine stimulation protocols, culture conditions, and scalability assessments. The company has conducted early-stage in-vitro cytotoxicity assays and in-vivo efficacy studies demonstrating the ability of expanded GDT cells to kill selected cancer cell lines. However, no formal GLP-compliant in-vivo toxicity studies have been completed to date for this platform. SL Science's business model is centered on developing partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer treatments.

SL Science Holding Ltd (NASDAQ:SLBT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for SLBT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for SLBT spans 6-K, SCHEDULE 13D, 20-F.

Recent high-impact activity:

  • SL Science Posts H1 2026: Revenue Up 23%, Net Loss Widens to $2.16M
  • SL Science Replaces ARK Pro CPA with TAAD LLP as Independent Auditor
  • SL Science Seeks FDA Orphan Drug Designation for GDT Cell Therapy in Glioblastoma
  • Newly Public SL Science Reports 35% Revenue Drop, 221% Net Loss Increase for FY2025
  • CEO & Chairman Discloses 59.53% Controlling Stake Post-SPAC Merger

Short Interest & Short Volume

1.41 days to cover

FINRA reported short interest of 49,966 shares in SLBT as of the October 30, 2026 settlement, a 36.6% increase from the prior period — about 1.4 days to cover at its recent average daily volume. On November 20, 2026, 44.7% of SLBT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)49,966 shares as of October 30, 2026
Change vs prior period▲ 36.6%
Days to cover1.41 at avg daily volume of 35,377
Daily short volume (FINRA facilities)44.7% of 13,185 shares on November 20, 2026
5-day average short volume47.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SLBT, detected from its recent SEC filings.

1 shelf registration

Resale Registration Filed · Lock-Up Expiration

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

SLBT files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with S →
$0.55
52-week range · as of 2026-10-26 $0.55 – $14.5
Market cap
$308.42M
Volume
28.6K (0.6× avg)
3-mo avg 51.7K
Live data · 2026-11-21 13:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLBT - Latest Insights

SLBT
Oct 26, 2026, 4:37 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.550 info
Change: -$0.690 (-56%) info
Market Cap: $308.418M info
SLBT
Aug 27, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $0.550 info
Change: -$2.18 (-80%) info
Market Cap: $308.418M info
SLBT
Jul 10, 2026, 8:55 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.56
Real-time Price: $0.550 info
Change: -$4.01 (-88%) info
Market Cap: $308.418M info
SLBT
Jun 18, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.61
Real-time Price: $0.550 info
Change: -$5.06 (-90%) info
Market Cap: $308.418M info
SLBT
Jun 18, 2026, 4:40 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $5.52
Real-time Price: $0.550 info
Change: -$4.97 (-90%) info
Market Cap: $308.418M info
SLBT
Jun 18, 2026, 4:30 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $5.69
Real-time Price: $0.550 info
Change: -$5.14 (-90%) info
Market Cap: $308.418M info
SLBT
Jun 15, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $5.44
Real-time Price: $0.550 info
Change: -$4.89 (-90%) info
Market Cap: $308.418M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets